CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total net revenue	$ 117,169	$ 115,533
COST OF REVENUE	78,937	73,959
Total gross profit	38,232	41,574
Operating expenses:
General and administrative	66,248	40,476
Research and development	7,713	2,456
Sales and marketing	16,299	13,749
Total operating expenses	90,260	56,681
Loss from operations	(52,028)	(15,107)
Interest (income) expense, net	1,301	1,177
Other (income) expenses, net	(168)	4,854
Loss before taxes	(53,161)	(21,138)
Income tax (benefit) expense	(3,753)	976
Net loss	$ (49,408)	$ (22,114)
NET LOSS PER SHARE
Basic (in dollars per share)	$ (0.40)	$ (0.19)
Diluted (in dollars per share)	$ (0.40)	$ (0.19)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	123,630	116,199
Diluted (in shares)	123,630	116,199
Clinical Services
Total net revenue	$ 98,791	$ 96,487
Total gross profit	33,524	34,922
Pharma Services
Total net revenue	18,378	19,046
Total gross profit	$ 4,708	$ 6,652